<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04378179</url>
  </required_header>
  <id_info>
    <org_study_id>55057</org_study_id>
    <nct_id>NCT04378179</nct_id>
  </id_info>
  <brief_title>Recognition of Heart Failure With Micro Electro-Mechanical Sensors (REFLECS)</brief_title>
  <official_title>Recognition of Heart Failure With Micro Electro-Mechanical Sensors (REFLECS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francois Haddad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Precordior Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will test the ability a novel wearable sensor based on a smartphone app (Precordior&#xD;
      CardioSignal app) in combination with a sensor device (Suunto Movesense sensor) to&#xD;
      non-invasively measure cardiac motion and function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart Failure (HF) is a syndrome where the heart is unable to pump or fill adequately to meet&#xD;
      the circulatory needs of the body. The main purpose of this study is to test the ability a&#xD;
      novel wearable sensor based on a smartphone app (Precordior CardioSignal app) in combination&#xD;
      with a sensor device (Suunto Movesense sensor) to non-invasively measure cardiac motion and&#xD;
      function. The phone and sensor are positioned on the chest and echocardiography is used as a&#xD;
      gold standard to assess cardiac mechanics including myocardial strain, cardiac torsion,&#xD;
      diastolic filling characteristics, hemodynamics including pressure estimates and stroke&#xD;
      volume.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Heart failure detection</measure>
    <time_frame>Baseline to Day 2</time_frame>
    <description>Test the ability of the Precordior sensor to detect heart failure with reduced ejection fraction, heart failure with preserved ejection fraction and pulmonary hypertension compared to control participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of differences in myocardial mechanics between admission and discharge</measure>
    <time_frame>up to 2 weeks (during admission) and 2 to 14 weeks (during follow-up visit).</time_frame>
    <description>The ability of the Precordior sensor to detect differences in myocardial mechanics as defined my myocardial longitudinal strain, hemodynamics and torsion analysis from admission and discharge.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Heart Failure</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>HFpEF</arm_group_label>
    <description>HF patients with preserved ejection fraction (HFpEF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFrEF</arm_group_label>
    <description>HF patients with reduced ejection fraction (HFrEF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH</arm_group_label>
    <description>Patients with Pulmonary hypertension (PH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Elective patients visiting hospital cardiology who are not diagnosed with either HFpEF or HFrHF or PH but meet other inclusion criteria and none of the exclusion criteria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients visiting Stanford Hospital and Clinics&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 21 years&#xD;
&#xD;
          -  Able to consent in English and follow study instructions&#xD;
&#xD;
          -  Patients hospitalized for heart failure with a diagnosis of HFpEF, HFrEF or PH, as&#xD;
             corresponding to each target patient group&#xD;
&#xD;
          -  Control patients will be enrolled from elective patients visiting the cardiology&#xD;
             service and who are not diagnosed with HFpEF or HFrEF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe cardiac valvular heart disease&#xD;
&#xD;
          -  Previous prosthetic cardiac valve&#xD;
&#xD;
          -  Pericardial disease including constrictive pericarditis or moderate or large&#xD;
             pericardial effusion&#xD;
&#xD;
          -  Mechanical circulatory support (including ECMO, LVADs etc).&#xD;
&#xD;
          -  Heart and/or lung transplant recipients&#xD;
&#xD;
          -  Major adverse cardiovascular event or surgery within 6 weeks of planned study&#xD;
             enrollment&#xD;
&#xD;
          -  Patients with pacemaker that has over 1% of beats paced&#xD;
&#xD;
          -  Chest wall disease&#xD;
&#xD;
          -  Pectus excavatum (severe)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  On Dialysis&#xD;
&#xD;
          -  Exclude at the clinical discretion of the Principal Investigators&#xD;
&#xD;
          -  Not possible to acquire echocardiography with sufficient quality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Haddad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francois Haddad, MD</last_name>
    <phone>650-723-4000</phone>
    <email>fhaddad@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karma Lhamo, MSc., CCRP</last_name>
    <email>karmalh@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Haddad</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Francois Haddad</investigator_full_name>
    <investigator_title>Clinical Professor Medicine - Med/Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

